Please provide your email address to receive an email when new articles are posted on . Urticaria patients taking Dupixent experienced an 8.64-point reduction in itch and 15.86-point reduction in ...
Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s the ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
TARRYTOWN, N.Y. and PARIS, June 28, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency will update the Dupixent® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback